ATREZZO: Phase II clinical trial with two parallel cohorts in patients with negative estrogen receptors or non-luminal disease according to PAM50, Treatment with atezolizumab in combination with trastuzumab and vinorelbine in advanced breast cancer/
INDEPENDENT CLINICAL TRIAL
Clinical trial information
- Promoter: SOLTI
- Phase: II
- Execution start: 13/01/2021
- End of execution: 28/02/2026
- IP: ISABEL BLANCAS LOPEZ-BARAJAS